Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PTAFR | P25105 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5254494 | 0.98 | HRH1 (0.57) | TDP1L3MBTL1HRH1TBXAS1CYP2A6 | |
| SCHEMBL5541158 | 0.98 | HRH1 (0.57) | TDP1L3MBTL1HRH1TBXAS1CYP2A6 | |
| SCHEMBL5046652 | 0.95 | CYP2A6 (0.54) | TDP1L3MBTL1HRH1TBXAS1CYP2A6 | |
| SCHEMBL271953 | 0.88 | CHRNA7 (0.52) | TDP1L3MBTL1HRH1TBXAS1CYP2A6 | |
| Hydrochloric Acid SCHEMBL27651479 | 0.87 | CHRNA7 (0.50) | TDP1L3MBTL1HRH1TBXAS1CYP2A6 | |
| SCHEMBL29485675 | 0.80 | TDP1 (0.80) | TDP1L3MBTL1HRH1TBXAS1CYP2A6 | |
| SCHEMBL724788 | 0.80 | TDP1 (0.80) | TDP1L3MBTL1HRH1TBXAS1CYP2A6 | |
| SCHEMBL5254433 | 0.80 | HRH1 (0.48) | TDP1L3MBTL1HRH1HRH4HRH3 | |
| SCHEMBL2517 | 0.79 | SIGMAR1 (0.48) | — | |
| SCHEMBL8658187 | 0.78 | HRH1 (0.81) | TDP1L3MBTL1HRH1TBXAS1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101166745-A | Thienopyridine compounds and methods of use thereof | FIBROGEN INC (US) | 2008-04-23 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TDP1 4666/4885L3MBTL1 1931/4885HRH1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.